Xenon Pharmaceuticals Inc.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people with neurological and psychiatric disorders, with a focus on areas of high unmet medical need such as epilepsy and depression.

Products & Services

Azetukalner (FOS):A product in development for focal onset seizures as part of Xenon's pipeline.

Azetukalner (PGTCS):A product targeting primary generalized tonic-clonic seizures within Xenon's clinical programs.

Azetukalner (MDD):A therapeutic candidate for major depressive disorder under Xenon's development pipeline.

Early-Stage Programs:Preclinical programs focused on developing new therapies for neurological disorders.

Partnered Programs:Collaborative projects with partners to advance therapeutic solutions in neuroscience.

Specialties

Neurology Therapies Epilepsy Treatment Depression Treatment Ion Channel Programs Kv7 Potassium Channel Openers

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 747500000 MR: - FA: approximately $747.5 million FAN: 747500000	D: 2026-03-12 FD: 2026-03-12	7 investors
2	RT: Public Offering T: - FT: Public Offering	A: 650000000 MR: - FA: $650.0 million FAN: 650000000	D: 2026-03-10 FD: 2026-03-10	7 investors
3	RT: Public Offering T: - FT: Public Offering	A: 500000000 MR: - FA: $500.0 million FAN: 500000000	D: 2026-03-09 FD: 2026-03-09	7 investors
4	RT: Public Offering T: - FT: Public Offering	A: 345000000 MR: - FA: 345.0 million FAN: 345000000	D: 2023-12-04 FD: 2023-12-04	5 investors
5	RT: Public Offering T: - FT: Public Offering	A: 225000000 MR: - FA: $225.0 million FAN: 225000000	D: 2023-11-29 FD: 2023-11-29	5 investors
6	RT: Public Offering T: - FT: Public Offering	A: 300000000 MR: - FA: 300.0 million FAN: 300000000	D: 2023-11-29 FD: 2023-11-29	5 investors

Public Offering Latest

2026-03-12

$747.5M

7 investors (Pro only)

Public Offering 2026-03-10

$650.0M

Public Offering 2026-03-09

$500.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

I

Ian Mortimer

President and Chief Executive Officer

D

Darren Cline

Chief Commercial Officer

A

Andrea DiFabio

Chief Legal Officer and Corporate Secretary

J

James Empfield

Executive Vice President, Drug Discovery

C

Christopher Kenney

Chief Medical Officer

S

Shelley McCloskey

Executive Vice President, Human Resources

View 12 more team members with Pro

Unlock Full Team Directory

Recent News